Diet, gut health, cardiovascular conditions and surgical history were identified as the most prevalent drivers of Alzheimer’s ...

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets ...

Corcept Therapeutics’ ALS drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate ...

Recent data from a single-arm trial suggest favorable-risk patients with HPV-associated oropharyngeal carcinoma may benefit from a deintensified regimen.

The pharma royalty funding market hit a record $10 billion in 2025. A single AI experiment that improved a cancer drug in ...

Investors are weighing Pfizer’s stable dividend and oncology-focused growth strategy against the higher-risk, higher-reward potential of biotech firms. Pfizer is navigating a post-COVID revenue ...

GeoVax CEO David Dodd highlights the need for U.S. manufacturing to reduce reliance on foreign biotech and strengthen ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...

We'll know more about the company's medium-term prospects by the end of the year.

Cochlear, CSL and Pro Medicus have been hard hit by disparate concerns, many of which investors suspect are structural rather ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund ...